CVRx, Inc. (CVRX) Form 8-K — Aug 6, 2026
CVRx reported second quarter 2026 revenue of $15.7 million, up 16% year over year, with U.S. revenue of $14.8 million up 21% and gross margin improving to 87% from 84%. Net loss narrowed to $14.0 million, or $0.53 per share, from $14.7 million, or $0.57 per share, a year earlier. On the reimbursement front, Humana issued a Medicare Advantage coverage policy for Barostim effective May 1, 2026, covering approximately 5.2 million members across 46 states.
Key figures
- Revenue
- $15.7 million
- Guidance
- FY2026 revenue $58.0-$60.0 million, gross margin 86%-87%, operating expenses $99.0-$101.0 million; Q3 2026 revenue $13.5-$14.5 million
- Net Income
- -$14.0 million
- Total Debt
- $58.6 million long-term debt
- Revenue Yoy
- 16%
- Total Assets
- $92.3 million
- Cash Position
- $64.6 million
- Shares Outstanding
- 26641597
- Rd expense
- $3.1 million (+27% YoY)
- Us revenue
- $14.8 million (+21% YoY)
- Sga expense
- $23.6 million (+1% YoY)
- Gross margin
- 87% (vs 84% prior year)
- Gross profit
- $13.7 million (+20% YoY)
- Europe revenue
- $0.9 million (-31% YoY)
- Q2 net cash used
- $8.9 million
- Us revenue units
- 466
- Six month revenue
- $30.5 million
- Six month net loss
- -$27.2 million
- Stockholders equity
- $20.0 million
- Europe revenue units
- 40
- Us sales territories
- 56
- Prior year q2 net loss
- -$14.7 million (-$0.57 per share)
- Humana ma members covered
- 5.2 million
- Active implanting centers us
- 258
Price after filing
1 day: +1.6%7 days: -46.4%30 days: -44.4%
Close on the filing date to close N calendar days later (from $5.49). Historical, not a forecast.
AI analysis
Red flags8 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.